The Inc. 5000 class of 2024 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges. Among this year’s top 500 companies, the average median three-year revenue growth rate is 1,637 percent. In all, this year’s Inc. 5000 companies have added 874,458 jobs to the economy over the past three years.
For complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to www.inc.com/inc5000. All 5000 companies are featured on Inc.com starting Tuesday, August 13, and the top 500 appear in the new issue of Inc. magazine, available on newsstands beginning Tuesday, August 20.
“One of the greatest joys of my job is going through the Inc. 5000 list,” says Mike Hofman, who recently joined Inc. as editor-in-chief. “To see all of the intriguing and surprising ways that companies are transforming sectors, from health care and AI to apparel and pet food, is fascinating for me as a journalist and storyteller. Congratulations to this year’s honorees, as well, for growing their businesses fast despite the economic disruption we all faced over the past three years, from supply chain woes to inflation to changes in the workforce.”
More about Inc. and the Inc. 5000
Inc. Business Media is the leading multimedia brand for entrepreneurs. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.’s award-winning work achieves a monthly brand footprint of over 40 million across various channels, including events, print, digital, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced yearly since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States.
The 2024 Inc. 5000 companies are ranked according to percentage revenue growth from 2020 to 2023. To qualify, companies must have been founded and generated revenue by March 31, 2020. Growth rates used to determine company rankings were calculated to four decimal places. For the full methodology and more information, visit Inc.’s website.
About Already Autism Health
Established in 2019, Already Autism Health is a nationally accredited provider of autism services. In 2024, we will serve over 3,000 children and currently employ over 450 people throughout North Carolina, South Carolina, Georgia, and Virginia. For additional information about Already Autism Health and our services, visit www.autismtherapyusa.com or contact us at 800-701-0498.
Building upon the popularity of the brand’s rapidly growing nutritional supplements, Nature Target launches its Multi-Collagen Peptides Powder to meet consumer demand for high-quality collagen that supports multiple aspects of health and wellness.
LOWELL, Mass., Aug. 15, 2024 /PRNewswire-PRWeb/ — Nature Target® is expanding its line of wellness products with the launch of its Multi-Collagen Peptides Powder, a versatile and high-quality supplement designed to support skin, hair, nails, joints, and gut health. Inspired by customers’ requests for a natural and convenient way to incorporate collagen into their daily routines, this product offers a perfect solution, now available on Amazon and online store in bulk, with the convenience of doorstep delivery.
Nature Target Multi-Collagen Peptides Powder provides a potent blend of five types of collagen derived from natural sources, making it an ideal choice for various lifestyle and dietary preferences. The powder is unflavored, easy to mix, and fits seamlessly into any beverage or recipe, offering a clean and natural boost to everyday nutrition.
“Our community challenged us to create a collagen product that not only delivers on quality but also caters to the diverse needs of our customers, such as those following Keto friendly or other specific diets,” said Kate, Product Development Manager at Nature Target.” We’re confident we’ve achieved this with our Multi-Collagen Peptides Powder, and we can’t wait to hear what our customers think.”
Nature Target Multi-Collagen Peptides Powder:
Grass-Fed, Hydrolyzed Collagen: Sourced from naturally raised, pasture-fed bovine, wild-caught fish, and free-range chickens.
Five Types of Collagen: Supports skin, hair, nails, joints, and gut health.
Unflavored and Easy to Mix: Perfect for blending into any drink or recipe.
Keto and Paleo-Friendly: Suitable for various dietary preferences, including those on keto and paleo diets.
Non-GMO and Gluten-Free: Aligns with clean eating standards, free from harmful additives.
“In our Amazon reviews, customers have expressed their delight in finding a collagen supplement that not only meets their health goals but also integrates easily into their daily lives. One customer mentioned how the powder has significantly improved their joint health, while another praised its versatility in recipes,” added Kate. “These insights have fueled our decisions in developing this product, and we’re thrilled to see the positive impact it’s making.”
At the same time, Nature Target are thrilled to announce the launch of our new online store, bringing Nature Target flagship organic product, directly to consumers. This exciting launch marks a significant milestone in our mission to promote overall wellness for human through natural and organic solutions.
Starting today, customers can visit our new online store at https://www.naturaltarget.us/ or Amazon to purchase the Multi-Collagen Peptides Powder and explore more about our product’s benefits. We offer a seamless shopping experience, with secure payment options and fast shipping to ensure our products reach your doorstep quickly.
For more information about Nature Target, visit naturetarget.us and follow @nature_target_official on Instagram.
About Nature Target®
Nature Target delivers high-quality, natural supplements designed to support overall health and well-being. Committed to using only the best ingredients, Nature Target ensures that every product is effective, safe, and easy to incorporate into daily routines. Nature Target’s product line includes Multi-Collagen Peptides Powder, CoQ10 for cellular energy support, Probiotics for gut health, and Omega-rich fish oil for heart and brain health. All Nature Target products are non-GMO, gluten-free, and align with clean eating principles.
Nature Target is committed to protecting the environment. Because air quality is vital to our health, a portion of the proceeds from every order placed through our online store will be directed to carbon removal companies vetted by Carbon Direct scientists. These companies use the funds to eliminate the carbon generated by our shipping activities.
Wellpointe Inc. Celebrates its Second Consecutive Appearance on the Prestigious Inc. 5000 List
FRESNO, Calif. , Aug. 15, 2024 /PRNewswire-PRWeb/ — Wellpointe Inc., a boutique residential assisted living provider that operates at the intersection of healthcare and real estate, is thrilled to announce its inclusion in the 2024 Inc. 5000 list, ranked at #1103. This marks the second consecutive year Wellpointe has earned a spot on the esteemed list, highlighting the company’s sustained growth and innovation within the industry.
The Inc. 5000 list, a hallmark of entrepreneurial success, ranks the fastest-growing private companies in the United States. Wellpointe Inc.’s impressive performance underscores its commitment to transforming residential assisted living through its coordinated and integrated system of care for high-acuity older adults with multiple chronic illnesses, including Alzheimer’s and other dementia.
“We are honored to be recognized once again on the Inc. 5000 list,” said George Kutnerian, Co-founder, President and CEO of Wellpointe Inc. “This achievement is a testament to the hard work and dedication of our team, the trust of our residents and their families, and our relentless pursuit of excellence and innovation in meeting the housing and care needs of our older adult population.”
The Inc. 5000 class of 2024 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges. In all, this year’s Inc. 5000 companies have added 874,458 jobs to the economy over the past three years.
“One of the greatest joys of my job is going through the Inc. 5000 list,” says Mike Hofman, who recently joined Inc. as editor-in-chief. “To see all of the intriguing and surprising ways that companies are transforming sectors, from health care to AI to apparel and pet food, is fascinating for me as a journalist and storyteller. Congratulations to this year’s honorees, as well, for growing their business fast despite the economic disruption we all faced over the past three years, from supply chain woes to inflation to changes in the workforce.”
About Wellpointe Inc.
Operating at the intersection of healthcare and real estate, Wellpointe Inc. is a leading provider of affordable, boutique-style residential assisted living services that specializes in offering a coordinated and integrated system of care to high-acuity older adults with multiple chronic illnesses, including Alzheimer’s and other dementia.
“This achievement is a testament to the hard work and dedication of our team, the trust of our residents and their families, and our relentless pursuit of excellence and innovation in meeting the housing and care needs of our older adult population.”
Research shows that pets can have a profound benefit for children with autism, including increased social interaction and improved social skills and behaviors. A HABRI-funded study also found significantly improved family harmony for families with a child with autism that had a dog compared to those without.*
“HABRI is grateful for the support of Ernie Els Pet Products, a company with a clear mission to empower pet owners to become champions for change and strengthen the human-animal bond,” said Steven Feldman, President of HABRI.
About Ernie Els Pet Products Ernie Els Pet Products offers pet owners a way to treat their pets while supporting a meaningful cause. Thoughtfully crafted pet products help support the autism community and encourage inclusivity through a direct partnership with the Els for Autism Foundation®. Discover more at https://ernieelspetproducts.com/.
About HABRI HABRI is a not-for-profit organization that funds innovative scientific research to document the health benefits of companion animals; educates the public about human-animal bond research; and advocates for the beneficial role of companion animals in society. For more information, please visit http://www.habri.org
Savings is taking a starring role in education planning, the survey found. Among the 94% of parents funding their children’s higher education, almost half say that savings is their primary way of doing so. All parents are saving substantially with 71% saving upwards of $5,000, 55% more than $10,000, and 36% more than $25,000 per child. All measures are up from prior years.
For the first time in the survey’s history, more than half of all parents said they are saving in a 529, also up significantly, with most of those making recurring monthly and quarterly contributions. One third of all parents say that 529s are their primary higher ed savings vehicle, followed by 20% using a CD or regular bank savings and 14% using mutual funds, stocks and bonds.
Additionally, 43% of parents said they are now using, or will use, a 529 for their own education, as they do for their own children.
“We are excited to see more families engaged in proactive saving, and recognizing the many benefits of using 529s for this purpose, as the way to prepare their children for both traditional college and career and technical schools,” said Chris McGee, Chair of CSF, a national nonprofit helping families in a lifetime of education saving. “Families are telling us that they are going to need ongoing education and skills-building and are investing in 529s to achieve that.”
Overall, parents of all ages embrace higher education but with a broader view of what that looks like today. Almost all parents say that career and technical education is as valuable to them as college, reflecting a recognition of the many highly skilled positions available require some postsecondary education but less than a four-year degree.
And, while traditional four-year college is still a prominent choice for families, 79% of parents say that the college experience needs to change to address future career paths. More than a third of that group say that classes should be more focused on career needs and training and another third say four-year schools need to adapt their programs to workforce needs. A solid minority of respondents also supports three-year degree options and more competency-based education.
Higher Ed Choices by Age Group
To get a sense of how families are making decisions and experiencing higher education now, the survey looked at parents at different stages in their education planning – those with students ages 18-25 and those with students ages 15-17 – and found a strong vote of confidence in their choices:
Among the 38% of respondents with college-age children (18-25), 56% are in four-year public or private college; 13% in career and technical education; 12% in community college; 2% in apprenticeships; 3% in the military, and 12% are not in higher ed.
86% of this group says their child feels that their choice is preparing them for the future.
71% of these parents feel that tuition and fees incurred for higher ed today represent a good value.
Among the 55% of respondents with children 15-17 years old: 69% expect them to attend a four-year public or private college, 17% career and technical education, 1% an apprenticeship, and 1% the military. 11% said they can’t yet predict their children’s choice.
What families know about 529s
The survey showed increasing awareness among parents about what 529s are and what types of expenses they can fund. The following reflect what parents know about 529s and what they are using them for:
66% – Traditional college, career and technical schools, community college, graduate school and certified apprenticeships
65% – Computers, books, technology software and the cost of internet
57% – Up to $10,000 to pay off student loans (lifetime limit per beneficiary and each sibling)
57% – Up to $10,000/year for K-12 tuition
51% – Unused funds may be eligible for rollover to a Roth IRA up to a lifetime limit of $35,000 per beneficiary
Parents’ Own Need for Higher Ed Savings
The survey also identified the parents’ own continuing education needs, with almost half saying they envision further education to maintain their current positions and careers, and over half saying that, if they change careers for any reason, they will need additional education or certification.
The CSF 2024 State of Higher Ed Savings survey of parents was conducted with more than 1,000 parents across the country via Survey Monkey. The College Savings Foundation (CSF) is a Washington, D.C.– based not-for-profit organization helping American families achieve their education savings goals for a lifetime. www.collegesavingsfoundation.org
14% supports early detection and interception efforts, aiming to develop and deliver tools enabling early diagnosis of pancreatic cancer; develop and optimize biomarkers enabling early detection in the general population; develop approaches for risk assessment and management of high-risk groups.
74% supports new drug development projects, aiming to accelerate the development of therapies; identify novel drug targets based on an understanding of the biology of pancreatic cancer initiation and progression; accelerate preclinical and clinical testing of novel drugs and combinations in pancreatic cancer.
12% supports personalized medicine studies, aiming to implement a personalized medicine program; better characterize and understand the heterogeneity of pancreatic cancer; develop tools to guide treatment decisions matching the right treatment to the right patient at the right time.
These 10 new grant commitments brought the Lustgarten Foundation’s total support in fiscal year 2024 to $23.7 million to fuel cutting-edge pancreatic cancer research.
This year’s grants included:
The LABS (Lustgarten Advancing Breakthrough Science) Program, a hallmark of the Foundation’s unique research strategy, made significant progress this year, with two out of the six laboratories up for renewal. After rigorous review, Lustgarten continued funding for both labs, located at Johns Hopkins University, led by Bert Vogelstein, MD, Director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Kimmel Cancer Center, and Elizabeth Jaffee, MD, Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The LABS Program provides long-term funding to promote the development of innovative ideas and speed the pace of discovery by incentivizing interdisciplinary team science, including groups with complementary expertise across the pipeline from target discovery and validation to preclinical development and clinical testing.
Lustgarten Foundation-AACR Career Development Awards Honoring Ruth Bader Ginsburg and John Robert Lewis awarded to Tracey W. Liu, PhD, assistant professor at the West Virginia University School of Medicine in Morgantown, WV, for her study “Expanding immunotherapy in pancreatic cancer by targeting myeloperoxidase,” and Christina G. Towers, PhD, assistant professor at the Salk Institute for Biological Studies in La Jolla, CA, for her study “Metastasis-Initiating Cells in Pancreatic Cancer.” The awards support trailblazing investigators committed to increasing the understanding and treatment of pancreatic cancer. These awards foster and grow the number of early-career women and underrepresented scientists receiving funding for pancreatic cancer research and honor the lives and legacies of two iconic Americans lost to pancreatic cancer.
LEAD (Lustgarten Equity, Accessibility, and Diversity) Grants awarded to Fiyinfolu Balogun, MD, PhD, Assistant Professor at Memorial Sloan Kettering Cancer Center, for his study “Investigating the molecular bases of pancreatic cancer disparities in underserved minority communities and increasing clinical trial recruitment employing linguistic intervention.” The LEAD Project aims to broaden inclusivity by actively recruiting and retaining patients from underrepresented minority groups in pancreatic cancer clinical trials.
Lustgarten Foundation-Swim Across America-AACR Early Detection Research Grant awarded to Renato Ostuni, PhD, Associate Professor at Università Vita-Salute San Raffaele, Milan, Italy, for his study “Targeting the PGE2-IL-1b axis for PDAC diagnosis and early treatment.” The Lustgarten Foundation-Swim Across America-AACR Pancreatic Cancer Early Detection Research Grant represents a joint effort to support innovative research to advance efforts toward the early detection and interception of pancreatic cancer.
Innovation and Collaboration Program Grant awarded to Linda Resar, MD, Professor of Medicine, Oncology, and Pathology, Johns Hopkins University for her study “Targeting HMGA1 Tumor-Stromal Signaling Networks in Pancreatic Cancer.” This program provides seed funding for highly innovative research projects with significant potential to accelerate the Lustgarten Foundation’s mission to transform pancreatic cancer into a curable disease.
Dr. Robert F. Vizza Lustgarten Clinical Accelerator Initiative (CAI) Grants awarded to Kim Reiss Binder, MD, Assistant Professor of Medicine, Division of Hematology-Oncology, Penn Medicine, for her study “Testing and Understanding Anti-CTLA4 Plus PARP Inhibitor Maintenance Therapy in Patients with Metastatic Pancreatic Cancer Who Have Achieved Stable Disease on FOLFIRINOX,” Andrew Lowy, Director of Surgical Oncology at UC San Diego, and Associate Clinical Director, Surgery, Moores Cancer Center, UC San Diego, in collaboration with Shweta Joshi, PhD Moores Cancer Center, UC San Diego, for their study “Syk-Targeted Therapy with Fostamatinib: A Promising Avenue to Enhance Chemotherapy Response in Pancreatic Cancer,” and Eric Christenson, MD, Assistant Professor, Johns Hopkins University School of Medicine, for his study “A pilot study comparing neoadjuvant and adjuvant GVAX vs a mutated KRAS peptide vaccine given with anti-PD-1 and anti-CD137 agonist for the treatment of surgically resectable pancreatic adenocarcinoma.” The CAI speeds the translation of basic research into the clinic by supporting novel, science-driven clinical trials. With three new trials added this year, there are now ten trials supported through this innovative program. In support of this, all data from CAI trials will also be integrated into Lustgarten’s United Clinical Information Database (LUCID), improving the data’s collective potential while making it accessible to the broader research community.
Through partnerships, the Lustgarten Foundation brings focus and strategy to pancreatic cancer research and maximizes our collective financial investment so we can fund the most high-risk, high-reward science. This year, Lustgarten and the Cancer Research Institute (CRI) announced a partnership focused exclusively on supporting pancreatic cancer immunotherapy research. The partnership, INSPIRE (Integrated Network for Supporting Pancreatic Cancer Immunotherapy Research Efforts), will encompass the established and ongoing adaptive platform trial, REVOLUTION, evaluating first-line chemo-immunotherapy treatment combinations for patients with metastatic pancreatic adenocarcinoma, and will also expand into new areas of pancreatic immunotherapy research. This next wave in immunotherapy research reflects a shared commitment to transforming pancreatic cancer into a curable disease.
“By breaking down industry silos to drive collaboration and information sharing, we are creating a culture of innovation and dedication to scientific rigor that is critical to solving the complexities of pancreatic cancer,” said Andrew Rakeman, Vice President of Research at the Lustgarten Foundation. “At the Lustgarten Foundation, we are confident that our collaborative and science-driven strategy will continue to fuel discoveries and advance breakthroughs faster than ever before.”
To date, the Lustgarten Foundation has funded more than $282.4 million in research grants and has been a driving force in every major advancement in pancreatic cancer research since its inception in 1998.
About Lustgarten Foundation The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, funding preeminent pancreatic cancer researchers, driving the pursuit of bold and innovative science toward earlier detection and better treatments, and transforming pancreatic cancer into a curable disease. The Foundation funds research where creative risks yield high rewards to accelerate and expand life-saving treatment options. We believe time is everything to patients and their families, and that community is power. Lustgarten programs and events provide people affected by pancreatic cancer a voice and a place to create hope, together. For more information about the Lustgarten Foundation, visit lustgarten.org and follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube.
“We are so proud to receive this recognition from Find Local Doctors. Our clinic uses advanced dental technology to ensure patients receive the highest level of oral care possible,” says Dr. Brian Mitchell.
More about Dental Care Acworth:
Dr. Brian Mitchell is an esteemed dentist who is trained in multiple facets of dentistry. This allows Dental Care Acworth to address the specific oral health concerns that patients face at each stage of life, ranging from gum disease and TMJ therapy to dentures and dental implants. He completed his undergraduate studies at The University of Georgia and then attended the Medical College of Georgia’s School of Dentistry, earning his dental degree. Dr. Arjan Hayer is an active member of the American Dental Association. He attended Lake Erie College of Osteopathic Medicine (LECOM) in Sarasota, Florida, and The University of Georgia. Dr. Hayer has completed many hours of continuing education in dental surgery, fixed and removable prosthodontics, Invisalign treatment and endodontics. For more information about Dental Care Acworth, located at 5552 Robin Road, Suite A in Acworth, GA, or to schedule an appointment, please visit http://www.dentistinacworth.com or call (678) 888-1554.
Key Miami-Dade business and hospitality leaders who have already signed up to participate in the 2024-2025 Teach-A-Thon include:
Hector J. Ponte, South Florida Regional Executive, Wells Fargo/Chair of the Greater Miami Chamber of Commerce
Mabel Morrison, Vice President, Product Management and Strategy
Quentin Nason, Founder, City Pay it Forward/Head of Corporate Development, Tetragon Financial Group Limited
Joe Natoli, Executive Vice President and Chief Administrative Officer, Baptist Health South Florida
Vivian Casals-Muñoz, Director of Community Relations, Hialeah Park
Paulette Phillips, Corporate & Private Chef, The 305 Chef
Pablo Pino, Market President South Florida Commercial, TD Bank/The Education Fund Board Chair
The Education Fund also proudly announces the success of its 2023-2024 Teach-A-Thon campaign. The Education Fund Teach-A-Thon united more than 100 business professionals with Miami-Dade County Public Schools teachers and students, raising nearly $60,000 and bringing the cumulative total of the Teach-A-Thon to $732,894.
This transformative initiative highlights the vital role of educators and prepares our future workforce. Public School Champions volunteered to stand in a teacher’s shoes for at least one lesson to learn more about a teacher’s daily experience. These professionals brought their real-life experiences to lessons, such as Financial Literacy, helping students see the relevancy of these subjects.
The campaign launched near the beginning of the 2023-2024 school year, fueled by active participation from professionals representing Wells Fargo, Assurant, City Pay It Forward, TD Bank, Blackstone, Biscayne Bay Brewing Company, Chen Medical Center, South Florida Business Journal, Kaufman Rossin, World Kinect, and many other local companies. These Public School Champions taught subjects such as financial literacy, science, technology, engineering, math, English, and social sciences. Each Champion also spread the word among their networks and helped fundraise for public schools.
“As a father of two M-DCPS educators and the husband of a retired public school teacher,” Hector J. Ponte says, “I bring a personal commitment to supporting initiatives like the Teach-A-Thon that truly make a difference in classrooms and in the lives of educators.”
During the 2023-24 school year, Ponte taught financial literacy to students in Navia Gomez’s class at Dante B. Fascell Elementary. Gomez remarked on her many years participating in the Teach-A-Thon, “As an educator, you really can’t put a price on what The Education Fund has done for us. When our kids come back and visit us, they let us know, ‘Because of that lesson that you did in class that was supported by The Education Fund, this is why I’m going into this type of career.’ As teachers, we don’t always get that feedback, but when those kids come back to see you, you know that you’ve made an impact. That’s a result of also being supported by The Education Fund because it takes a village, as they say, for us to make a difference in our kids’ lives.”
President Linda Lecht reflected on the profound impact of The Education Fund Teach-A-Thon, “Teaching quality is the single greatest determinant of student achievement. The business community’s participation in the Teach-A-Thon serves as a tangible support system for our teachers, further helping us recruit and retain the best for our students.”
Top Public School Champions and Their Companies The Education Fund expresses its heartfelt appreciation to the 2023-24 Public School Champions and their companies. Their generosity has played a pivotal role in making this initiative impactful and shaping a brighter future for Miami-Dade County Public Schools:
Top Public School Champions and Their Companies Included: Diamond Awards ($15,000 or More):
Quentin Nason, City Pay it Forward
Platinum Awards ($5,000 or More):
Paulette Phillips, The 305 Chef
Carolyn Guerra, TD Bank
Gold Awards ($2,500 or More):
Pablo Pino, TD Bank
Nick Tootle, Kaufman Rossin
Edwin Rodriguez
Joe Natoli, Baptist Health South Florida
The Education Fund extends gratitude to all teachers, donors, and Public School Champions for their collective efforts, making the Teach-A-Thon campaign a success. For more information or involvement in future initiatives, visit educationfund.org.
About The Education Fund The Education Fund strives to bring innovative methods to local public schools, raise awareness about public education, and encourage private sector investment. Recognized for improving student outcomes, The Education Fund has received prestigious awards, including the TD Ready Challenge, Greater Miami Chamber’s NOVO Award for Non-Profit Excellence, and the Blue Foundation’s Sapphire Prize. Learn more at educationfund.org.
In this webinar, the expert speakers will delve into the submission process, highlighting the various types of submissions and the role of medical writing at each stage. They will cover the common requirements for technical documents and outline the differences in application requirements across major regions such as the US, EU, UK, China and Japan.
The importance of leadership, precise timing and strategic planning in the submission process will be discussed, emphasizing the need for assembling a key team, setting clear expectations and establishing effective working rules. The webinar will also explore how to consistently incorporate standards across documents, clarify key messages and seamlessly integrate pivotal clinical trial documents.
Moreover, they will examine how individual components of an application contribute to the broader submission strategy, focusing on maintaining quality, the necessity of tracking and documentation, resolving conflicts efficiently and preparing for multiple submissions or follow-up requests.
Register for this webinar today to learn about the specific requirements for regulatory submissions across major global regions, the importance of strategic planning and how to enhance the coherence and quality of technical documentation.
Join experts from ICON, Keith Dawes, Senior Director, Medical Writing; and Tim Weber, PhD, Senior Director, Medical Writing, for the live webinar on Tuesday, September 10, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Regulatory Submission Writing for NDA Success.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Transitioning to the USA for later-stage trials, particularly Phase II, is crucial for aligning with US Food and Drug Administration (FDA) regulations and capitalizing on the diverse patient population. This diversity is especially important in oncology, where genetic variability and differing tumor biology across populations can impact treatment efficacy and safety.
Conducting trials in the USA also facilitates entry into the world’s largest pharmaceutical market, enhancing commercial prospects for oncology therapies. For this purpose, an integrated approach helps ensure a seamless transition from Australia to the USA as it helps maintain consistency in trial design, data collection and regulatory compliance while maximising the R&D rebate. It also mitigates the risks associated with navigating different regulatory landscapes.
In oncology, early-phase trials are pivotal not only for assessing safety and tolerability but also for generating early efficacy data in cancer patient populations. Designing trials that provide critical insights into a drug’s therapeutic potential accelerates the development process and in subsequent trial phases helps increase investor confidence and attract potential licensing partners, which in turn de-risks the program and maximizes return on investment.
Register for this webinar today to learn about the strategic advantages of early-phase oncology clinical development in Australia and the USA and how it helps ensure innovative cancer therapies reach the market.
Join experts from Avance Clinical, Gabriel Kremmidiotis, Chief Scientific Officer; and Alex Kavros, Executive Vice President, Scientific & Regulatory Affairs, for the live webinar on Monday, September 9, 2024, at 10am PDT (1pm EDT).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
